BioDelivery Sciences International, Inc. (NASDAQ:BDSI) was the recipient of a significant drop in short interest in September. As of September 29th, there was short interest totalling 1,883,046 shares, a drop of 50.3% from the September 15th total of 3,787,249 shares. Currently, 3.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 709,450 shares, the short-interest ratio is currently 2.7 days.

In other BioDelivery Sciences International news, insider Mark A. Sirgo sold 201,373 shares of the firm’s stock in a transaction that occurred on Thursday, September 21st. The shares were sold at an average price of $2.84, for a total value of $571,899.32. Following the sale, the insider now owns 1,509,262 shares in the company, valued at $4,286,304.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Mark A. Sirgo sold 65,405 shares of the firm’s stock in a transaction that occurred on Wednesday, September 20th. The shares were sold at an average price of $2.75, for a total transaction of $179,863.75. Following the completion of the sale, the chief executive officer now owns 1,509,262 shares in the company, valued at approximately $4,150,470.50. The disclosure for this sale can be found here. Insiders sold 402,127 shares of company stock worth $1,142,798 in the last 90 days. Company insiders own 9.00% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. Valley National Advisers Inc. boosted its position in BioDelivery Sciences International by 59.0% during the 2nd quarter. Valley National Advisers Inc. now owns 37,715 shares of the specialty pharmaceutical company’s stock valued at $106,000 after buying an additional 14,000 shares during the period. Stonepine Capital Management LLC boosted its position in BioDelivery Sciences International by 22.2% during the 2nd quarter. Stonepine Capital Management LLC now owns 3,477,673 shares of the specialty pharmaceutical company’s stock valued at $9,737,000 after buying an additional 632,853 shares during the period. KCG Holdings Inc. boosted its position in BioDelivery Sciences International by 469.9% during the 1st quarter. KCG Holdings Inc. now owns 110,728 shares of the specialty pharmaceutical company’s stock valued at $210,000 after buying an additional 91,297 shares during the period. Grandeur Peak Global Advisors LLC boosted its position in BioDelivery Sciences International by 5.9% during the 1st quarter. Grandeur Peak Global Advisors LLC now owns 1,007,006 shares of the specialty pharmaceutical company’s stock valued at $1,913,000 after buying an additional 56,550 shares during the period. Finally, GSA Capital Partners LLP boosted its position in BioDelivery Sciences International by 10.1% during the 2nd quarter. GSA Capital Partners LLP now owns 488,767 shares of the specialty pharmaceutical company’s stock valued at $1,369,000 after buying an additional 44,700 shares during the period. 41.43% of the stock is owned by institutional investors and hedge funds.

BioDelivery Sciences International (NASDAQ BDSI) opened at 2.875 on Tuesday. BioDelivery Sciences International has a one year low of $1.50 and a one year high of $3.60. The firm has a market cap of $159.49 million, a price-to-earnings ratio of 102.679 and a beta of 0.95. The stock’s 50 day moving average is $2.94 and its 200-day moving average is $2.60.

BioDelivery Sciences International (NASDAQ:BDSI) last released its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.04). BioDelivery Sciences International had a net margin of 3.34% and a return on equity of 14.64%. The business had revenue of $8.70 million for the quarter, compared to the consensus estimate of $8.45 million. During the same period in the prior year, the business posted ($0.31) EPS. BioDelivery Sciences International’s revenue for the quarter was up 74.0% on a year-over-year basis. On average, equities research analysts expect that BioDelivery Sciences International will post $0.12 earnings per share for the current fiscal year.

BDSI has been the topic of a number of research analyst reports. Janney Montgomery Scott raised their target price on shares of BioDelivery Sciences International from $3.00 to $4.00 and gave the company a “fair value” rating in a research report on Monday, July 24th. Zacks Investment Research upgraded shares of BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a report on Wednesday, July 12th. HC Wainwright reiterated a “buy” rating and set a $4.00 price target on shares of BioDelivery Sciences International in a report on Friday, June 23rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of BioDelivery Sciences International in a report on Sunday, August 20th. Finally, Piper Jaffray Companies set a $4.00 price target on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $4.29.

WARNING: “BioDelivery Sciences International, Inc. (BDSI) Short Interest Update” was posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://www.watchlistnews.com/biodelivery-sciences-international-inc-bdsi-short-interest-update/1635449.html.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.